HIV Mutation Detail Information

Virus Mutation HIV Mutation N188A


Basic Characteristics of Mutations
Mutation Site N188A
Mutation Site Sentence The sCD4-induced reduction in PG9 binding was observed for either full-length or cytoplasmic tail-deleted Env complexes expressed on the surface of 293T or HOS cells;similar results were obtained with Envs derived from wild-type HIV-1YU2 or an HIV-1JR-FL variant with E168K + N188A changes in V1/V2, which restores the integrity of the PG9 epitope in that HIV-1 strain (Supplementary Fig. 10).
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region gp120
Standardized Encoding Gene Env  
Genotype/Subtype HIV-1
Viral Reference -
Functional Impact and Mechanisms
Disease Cell line    
Immune Y
Target Gene CCR5    CD4   
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location America
Literature Information
PMID 25174000
Title A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry
Author Herschhorn A,Gu C,Espy N,Richard J,Finzi A,Sodroski JG
Journal Nature chemical biology
Journal Info 2014 Oct;10(10):845-52
Abstract Binding to the primary receptor, CD4, triggers conformational changes in the metastable HIV-1 envelope glycoprotein (Env) trimer ((gp120-gp41)3) that are important for virus entry into host cells. These changes include an 'opening' of the trimer, creation of a binding site for the CCR5 co-receptor and formation and/or exposure of a gp41 coiled coil. Here we identify a new compound, 18A (1), that specifically inhibits the entry of a wide range of HIV-1 isolates. 18A does not interfere with CD4 or CCR5 binding, but it inhibits the CD4-induced disruption of quaternary structures at the trimer apex and the exposure of the gp41 HR1 coiled coil. Analysis of HIV-1 variants with increased or reduced sensitivity to 18A suggests that the inhibitor can distinguish distinct conformational states of gp120 in the unliganded Env trimer. The broad-range activity and observed hypersensitivity of resistant mutants to antibody neutralization support further investigation of 18A.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.